EGFR and non-small cell lung carcinoma: A pooled analysis revealed an overall improvement in the PFS for older adult patients with advanced EGFR-mutated NSCLC who were treated with dacomitinib and osimertinib (HR = 0.654, 95% CI: 0.474 to 0.903; p < 0.01; Figure 3).